Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Metastatic Triple-Negative Breast Carcinoma
Interventions: DIAGNOSTIC_TEST: 89Zr-atezolizumab PET/CT
Sponsor: Karolinska University Hospital